SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS)
CUSIP: 78397T202
Q3 2024 13F Holders as of 30 Sep 2024
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Shares outstanding
- 73,850,758
- Total 13F shares
- 3,141,736
- Share change
- +25,373
- Total reported value
- $8,482,377
- Price per share
- $2.70
- Number of holders
- 24
- Value change
- +$68,507
- Number of buys
- 6
- Number of sells
- 5
Quarterly Holders Quick Answers
What is CUSIP 78397T202?
CUSIP 78397T202 identifies SABS - SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 78397T202:
Top shareholders of SABS - SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Edward D. Hamilton |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
9,456,382
mixed-class rows
|
$9,348,396 | — | 22 Oct 2021 | |
| BVF INC/IL |
13F
|
Company |
1.2%
|
917,826
|
$2,845,261 | — | 30 Jun 2024 | |
| Ilan Katz |
3/4/5
|
Director, 10%+ Owner |
—
class O/S missing
|
3,049,325
|
$2,683,406 | — | 13 Oct 2021 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
1%
|
766,946
|
$2,377,533 | — | 30 Jun 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.62%
|
459,168
|
$1,423,421 | — | 30 Jun 2024 | |
| Sessa Capital IM, L.P. |
13F
|
Company |
0.62%
|
458,457
|
$1,421,217 | — | 30 Jun 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.37%
|
276,336
|
$856,641 | — | 30 Jun 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.08%
|
59,415
|
$184,222 | — | 30 Jun 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.07%
|
52,784
|
$163,630 | — | 30 Jun 2024 | |
| Pathstone Holdings, LLC |
13F
|
Company |
0.07%
|
50,650
|
$157,016 | — | 30 Jun 2024 | |
| FIRST MANHATTAN CO. LLC. |
13F
|
Company |
0.03%
|
24,577
|
$76,189 | — | 30 Jun 2024 | |
| First PREMIER Bank |
13F
|
Company |
0.03%
|
19,386
|
$60,000 | — | 30 Jun 2024 | |
| INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC |
13F
|
Company |
0.03%
|
19,201
|
$59,523 | — | 30 Jun 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.02%
|
13,752
|
$42,631 | — | 30 Jun 2024 | |
| LMR Partners LLP |
13F
|
Company |
—
class O/S missing
|
539,588
|
$25,576 | — | 30 Jun 2024 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0.01%
|
4,534
|
$14,055 | — | 30 Jun 2024 | |
| Shaolin Capital Management LLC |
13F
|
Company |
—
class O/S missing
|
249,143
|
$11,809 | — | 30 Jun 2024 | |
| MORGAN STANLEY |
13F
|
Company |
—
mixed-class rows
|
147,138
mixed-class rows
|
$9,108 | — | 30 Jun 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
—
mixed-class rows
|
2,441
mixed-class rows
|
$7,420 | — | 30 Jun 2024 | |
| Yakira Capital Management, Inc. |
13F
|
Company |
—
class O/S missing
|
108,485
|
$5,142 | — | 30 Jun 2024 | |
| Michael G. King Jr. |
3/4/5
|
CHIEF FINANCIAL OFFICER |
—
mixed-class rows
|
120,000
mixed-class rows
|
$4,400 | — | 21 Feb 2024 | |
| Princeton Global Asset Management LLC |
13F
|
Company |
0%
|
500
|
$1,550 | — | 30 Jun 2024 | |
| Walleye Capital LLC |
13F
|
Company |
—
class O/S missing
|
23,258
|
$1,102 | — | 30 Jun 2024 | |
| Walleye Trading LLC |
13F
|
Company |
—
class O/S missing
|
15,505
|
$735 | — | 30 Jun 2024 | |
| WOLVERINE ASSET MANAGEMENT LLC |
13F
|
Company |
—
class O/S missing
|
15,319
|
$726 | — | 30 Jun 2024 | |
| GS Investments, Inc. |
13F
|
Company |
0%
|
200
|
$620 | — | 30 Jun 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
—
mixed-class rows
|
365
mixed-class rows
|
$520 | — | 30 Jun 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
106
|
$329 | — | 30 Jun 2024 | |
| HARBOUR INVESTMENTS, INC. |
13F
|
Company |
0%
|
50
|
$155 | — | 30 Jun 2024 | |
| NewEdge Advisors, LLC |
13F
|
Company |
—
class O/S missing
|
1,072
|
$50 | — | 30 Jun 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0%
|
6
|
$19 | — | 30 Jun 2024 | |
| UBS Group AG |
13F
|
Company |
—
class O/S missing
|
56
|
$3 | — | 30 Jun 2024 | |
| Russell P. Beyer |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
275,000
|
— | — | 14 Mar 2023 | |
| Charles Hiram Randall |
3/4/5
|
Chief Strategy Officer |
—
mixed-class rows
|
157,313
mixed-class rows
|
— | — | 22 Oct 2021 | |
| Mervyn Turner |
3/4/5
|
Director |
—
mixed-class rows
|
79,192
mixed-class rows
|
— | — | 22 Oct 2021 | |
| Hua Wu |
3/4/5
|
SVP Research & Product Dev. |
—
mixed-class rows
|
43,823
mixed-class rows
|
— | — | 22 Oct 2021 | |
| Frederick Finnegan |
3/4/5
|
Chief Business Officer |
—
class O/S missing
|
23,453
|
— | — | 16 Mar 2022 | |
| Thomas Charles Luke |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
20,519
|
— | — | 16 Mar 2022 | |
| Jeffrey G. Spragens |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 15 Jul 2024 | |
| Bruce Kipp Erickson |
3/4/5
|
Chief Operating Officer |
—
class O/S missing
|
18,196
|
— | — | 16 Mar 2022 | |
| Carlos N. Carillo |
3/4/5
|
SVP Regulatory Affairs |
—
class O/S missing
|
17,681
|
— | — | 22 Oct 2021 | |
| Melissa Vera Ullerich |
3/4/5
|
Chief Communications Officer |
—
class O/S missing
|
16,405
|
— | — | 16 Mar 2022 | |
| Jerry Lynn Pommer |
3/4/5
|
Chief Compliance Officer |
—
class O/S missing
|
15,172
|
— | — | 16 Mar 2022 | |
| David Charles Link |
3/4/5
|
Director |
—
class O/S missing
|
9,305
|
— | — | 15 Jul 2024 | |
| Christine Hamilton Power |
3/4/5
|
Director |
—
class O/S missing
|
6,773
|
— | — | 15 Jul 2024 |
Institutional Holders of SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) as of Q3 2024
As of 30 Sep 2024,
SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) was held by
24 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,141,736 shares.
The largest 10 holders included
BVF INC/IL, RTW INVESTMENTS, LP, MARSHALL WACE, LLP, Sessa Capital IM, L.P., VANGUARD GROUP INC, HB Wealth Management, LLC, GEODE CAPITAL MANAGEMENT, LLC, MILLENNIUM MANAGEMENT LLC, Pathstone Holdings, LLC, and FIRST MANHATTAN CO. LLC..
This page lists
25
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
21
Q3 2024 holders
24
Holder diff
3
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 Value $ | Q3 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.